Advertisement
CODX vs STXS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CODX is a Hold and STXS is a Hold.
CODX sees MACD Histogram just turned negative
CODX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 37 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CODX entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where CODX advanced for three days, in 174 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.310) is normal, around the industry mean (2.874). P/E Ratio (-0.022) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
STXS in downward trend: price dove below 50-day moving average on September 23, 2026
STXS moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 31 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STXS as a result. In 86 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for STXS turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 44 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for STXS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.143) is normal, around the industry mean (4.961). P/E Ratio (-4.145) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CODX | STXS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 95 | 88 | |
P/E GROWTH RATING 1..100 | 6 | 15 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CODX's Valuation (51) in the Biotechnology industry is somewhat better than the same rating for STXS (96) in the Medical Specialties industry. This means that CODX’s stock grew somewhat faster than STXS’s over the last 12 months.
CODX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that CODX’s stock grew similarly to STXS’s over the last 12 months.
CODX's SMR Rating (99) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that CODX’s stock grew similarly to STXS’s over the last 12 months.
STXS's Price Growth Rating (88) in the Medical Specialties industry is in the same range as CODX (95) in the Biotechnology industry. This means that STXS’s stock grew similarly to CODX’s over the last 12 months.
CODX's P/E Growth Rating (6) in the Biotechnology industry is in the same range as STXS (15) in the Medical Specialties industry. This means that CODX’s stock grew similarly to STXS’s over the last 12 months.
| CODX | STXS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 84% |
| Advances ODDS (%) | 11 days ago 83% | N/A |
| Declines ODDS (%) | 1 day ago 89% | 2 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 71% | N/A |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CODX’s FA Score shows that 1 FA rating(s) are green while STXS’s FA Score has 1 green FA rating(s).
- CODX’s FA Score: 1 green, 4 red.
- STXS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CODX’s TA Score shows that 4 TA indicator(s) are bullish while STXS’s TA Score has 3 bullish TA indicator(s).
- CODX’s TA Score: 4 bullish, 5 bearish.
- STXS’s TA Score: 3 bullish, 5 bearish.
Price Growth
CODX (@Medical/Nursing Services) experienced а -16.02% price change this week, while STXS (@Pharmaceuticals: Other) price change was -5.25% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
Reported Earning Dates
CODX is expected to report earnings on Nov 12, 2026.
STXS is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
CODX and
Correlation & Price change
A.I.dvisor tells us that CODX and MBOT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CODX and MBOT's prices will move in lockstep.
| Ticker / NAME | Correlation To CODX | 1D Price Change % | ||
|---|---|---|---|---|
| CODX | 100% | -11.99% | ||
| MBOT - CODX | 31% Poorly correlated | +0.19% | ||
| NVST - CODX | 30% Poorly correlated | +3.36% | ||
| AIMD - CODX | 30% Poorly correlated | -4.56% | ||
| ILMN - CODX | 27% Poorly correlated | -4.76% | ||
| STXS - CODX | 25% Poorly correlated | +0.31% | ||
More | ||||
STXS and
Correlation & Price change
A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.
| Ticker / NAME | Correlation To STXS | 1D Price Change % | ||
|---|---|---|---|---|
| STXS | 100% | +0.31% | ||
| SMTI - STXS | 38% Loosely correlated | +0.34% | ||
| TWST - STXS | 36% Loosely correlated | -9.16% | ||
| CERS - STXS | 35% Loosely correlated | -3.35% | ||
| VCYT - STXS | 33% Poorly correlated | -0.39% | ||
| SHC - STXS | 32% Poorly correlated | +2.03% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TMF | 29.78 | 1.56 | +5.53% |
| Direxion Daily 20+ Year Treasury Bull 3X ETF (TMF) | |||
| VDIG | 65.31 | 0.07 | +0.11% |
| Vanguard Wellington Dividend Growth Active ETF (VDIG) | |||
| ACSI | 76.13 | N/A | N/A |
| American Customer Satisfaction ETF (ACSI) | |||
| ULE | 11.88 | -0.05 | -0.39% |
| ProShares Ultra Euro (ULE) | |||
| LRGE | 87.06 | -2.24 | -2.51% |
| ClearBridge Large Cap Growth Select ETF (LRGE) | |||